{
    "hands_on_practices": [
        {
            "introduction": "While the gold standard for randomization is the individual, it is not always feasible or desirable, particularly in public health settings where interventions are delivered to groups. This practice problem delves into the design of Cluster Randomized Trials (CRTs), where entire groups of individuals, such as schools or clinics, are randomized. You will learn how to account for the inherent correlation among individuals within a cluster by calculating the variance inflation factor and adjusting the total sample size to maintain the study's statistical power .",
            "id": "4639876",
            "problem": "A two-arm parallel Cluster Randomized Trial (CRT) is planned to evaluate a public health intervention. Due to expected contamination in individually randomized trials, clusters (for example, clinics or schools) will be randomized. Each cluster will contribute exactly $m=20$ individuals, and the correlation among outcomes within a cluster is quantified by the intracluster correlation coefficient (ICC), defined as $\\rho$, where the ICC is the ratio of the covariance between two distinct individuals within the same cluster to the marginal variance of an individual outcome under an exchangeable correlation structure. Suppose an Individually Randomized Trial (IRT) yields a total sample size requirement of $N=400$ individuals to attain specified Type I error and power for a given effect size, under the assumption of independence of individual responses.\n\nStarting from the definition of the intracluster correlation coefficient and the variance of the sample mean under an exchangeable correlation structure with equal cluster sizes, derive the variance inflation factor due to clustering, and then use it to:\n\n1. Compute the cluster-adjusted effective sample size that would be obtained if a total of $N=400$ individuals were enrolled under the CRT with $m=20$ and $\\rho=0.05$.\n2. Compute the required number of clusters per arm to achieve the same effective sample size as the IRT, assuming equal allocation of clusters and individuals between arms and constant cluster size $m$.\n\nExpress both answers as exact real numbers with no rounding. Provide the two results in order as a row vector. No units are required.",
            "solution": "The user has provided a problem from the field of epidemiology and biostatistics concerning the design of a Cluster Randomized Trial (CRT).\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n-   Study Design: Two-arm parallel Cluster Randomized Trial (CRT).\n-   Individuals per cluster (cluster size): $m=20$.\n-   Intracluster Correlation Coefficient (ICC): $\\rho$.\n-   Definition of ICC: $\\rho$ is the ratio of the covariance between two distinct individuals within the same cluster to the marginal variance of an individual outcome, under an exchangeable correlation structure.\n-   Sample size requirement for an equivalent Individually Randomized Trial (IRT): $N=400$.\n-   Specific value of ICC for calculation: $\\rho=0.05$.\n-   Task 1: Compute the cluster-adjusted effective sample size for a CRT with a total of $N=400$ individuals, $m=20$, and $\\rho=0.05$.\n-   Task 2: Compute the required number of clusters per arm to achieve the same effective sample size as the IRT ($400$), with $m=20$, $\\rho=0.05$, and equal allocation.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientific Grounding:** The problem is based on established statistical principles for the design and analysis of CRTs. The concepts of ICC, Variance Inflation Factor (VIF), and effective sample size are standard and correctly defined. The problem is scientifically sound.\n-   **Well-Posedness:** The problem is well-posed, providing all necessary parameters ($N$, $m$, $\\rho$) and clear objectives. A unique and meaningful solution can be derived.\n-   **Objectivity:** The problem is stated in precise, objective language, free from ambiguity or subjective claims.\n\n**Step 3: Verdict and Action**\nThe problem is valid. The premises are scientifically sound, the data are consistent, and the questions are well-posed. A rigorous solution can be constructed.\n\n### Solution Derivation\n\nThe first step is to derive the Variance Inflation Factor (VIF) due to clustering. Let $Y_{ij}$ be the outcome variable for the $j$-th individual (where $j=1, 2, \\dots, m$) in the $i$-th cluster. The problem states an exchangeable correlation structure. Let the marginal variance of each outcome be $\\text{Var}(Y_{ij}) = \\sigma^2$. The covariance between two distinct individuals in the same cluster is $\\text{Cov}(Y_{ij}, Y_{ik}) = \\rho \\sigma^2$ for $j \\neq k$.\n\nConsider the sample mean for a single cluster $i$:\n$$ \\bar{Y}_i = \\frac{1}{m} \\sum_{j=1}^{m} Y_{ij} $$\nThe variance of this sample mean is:\n$$ \\text{Var}(\\bar{Y}_i) = \\text{Var}\\left(\\frac{1}{m} \\sum_{j=1}^{m} Y_{ij}\\right) = \\frac{1}{m^2} \\text{Var}\\left(\\sum_{j=1}^{m} Y_{ij}\\right) $$\nThe variance of the sum is the sum of all elements in the covariance matrix of the $m$ individuals within the cluster. This consists of $m$ variance terms on the diagonal and $m(m-1)$ covariance terms off the diagonal.\n$$ \\text{Var}\\left(\\sum_{j=1}^{m} Y_{ij}\\right) = \\sum_{j=1}^{m} \\text{Var}(Y_{ij}) + \\sum_{j \\neq k} \\text{Cov}(Y_{ij}, Y_{ik}) $$\n$$ \\text{Var}\\left(\\sum_{j=1}^{m} Y_{ij}\\right) = m\\sigma^2 + m(m-1)\\rho\\sigma^2 = m\\sigma^2 [1 + (m-1)\\rho] $$\nSubstituting this back into the expression for $\\text{Var}(\\bar{Y}_i)$:\n$$ \\text{Var}(\\bar{Y}_i) = \\frac{1}{m^2} \\left( m\\sigma^2 [1 + (m-1)\\rho] \\right) = \\frac{\\sigma^2}{m} [1 + (m-1)\\rho] $$\nFor an Individually Randomized Trial (IRT), the observations are independent ($\\rho=0$), and the variance of the mean of $m$ individuals would be $\\frac{\\sigma^2}{m}$. The Variance Inflation Factor (VIF), also known as the design effect, is the ratio of the variance under clustering to the variance under independence.\n$$ \\text{VIF} = \\frac{\\text{Var}_{\\text{clustered}}(\\bar{Y}_i)}{\\text{Var}_{\\text{independent}}(\\bar{Y}_i)} = \\frac{\\frac{\\sigma^2}{m}[1 + (m-1)\\rho]}{\\frac{\\sigma^2}{m}} = 1 + (m-1)\\rho $$\nThis factor quantifies the degree to which the sample variance is inflated due to the within-cluster correlation.\n\nNow, we can use this derived VIF to solve the two parts of the problem. We are given $m=20$ and $\\rho=0.05$.\nFirst, we compute the numerical value of the VIF:\n$$ \\text{VIF} = 1 + (20-1)(0.05) = 1 + (19)(0.05) = 1 + 0.95 = 1.95 $$\n\n**1. Compute the cluster-adjusted effective sample size.**\nThe effective sample size ($N_{\\text{eff}}$) is the sample size of an IRT that would provide the same statistical power as the CRT with its total sample size $N$. It is calculated by dividing the total number of individuals in the CRT by the VIF.\nGiven a total enrollment of $N=400$ individuals in the CRT:\n$$ N_{\\text{eff}} = \\frac{N}{\\text{VIF}} = \\frac{400}{1.95} $$\nTo express this as an exact fraction:\n$$ N_{\\text{eff}} = \\frac{400}{\\frac{195}{100}} = \\frac{400 \\times 100}{195} = \\frac{40000}{195} $$\nThe greatest common divisor of $40000$ and $195$ is $5$.\n$$ N_{\\text{eff}} = \\frac{40000 \\div 5}{195 \\div 5} = \\frac{8000}{39} $$\n\n**2. Compute the required number of clusters per arm.**\nThe goal is to achieve an effective sample size equal to that of the reference IRT, which is $N_{\\text{eff}} = 400$. Let $N_{CRT}$ be the total number of individuals required for this CRT. The VIF remains $1.95$ because $m$ and $\\rho$ are unchanged.\nWe use the same relationship and solve for $N_{CRT}$:\n$$ N_{\\text{eff}} = \\frac{N_{CRT}}{\\text{VIF}} \\implies 400 = \\frac{N_{CRT}}{1.95} $$\n$$ N_{CRT} = 400 \\times 1.95 = 400 \\times \\left(2 - 0.05\\right) = 800 - 20 = 780 $$\nA total of $780$ individuals are required. Since each cluster contributes $m=20$ individuals, the total number of clusters, $K$, needed is:\n$$ K = \\frac{N_{CRT}}{m} = \\frac{780}{20} = 39 $$\nThe problem asks for the number of clusters per arm, assuming a two-arm trial with equal allocation.\n$$ \\text{Clusters per arm} = \\frac{K}{2} = \\frac{39}{2} $$\nAs the problem asks for an exact real number, $\\frac{39}{2}$ (or $19.5$) is the required answer.\n\nThe two results are $\\frac{8000}{39}$ and $\\frac{39}{2}$.",
            "answer": "$$ \\boxed{\\begin{pmatrix} \\frac{8000}{39} & \\frac{39}{2} \\end{pmatrix}} $$"
        },
        {
            "introduction": "A core strength of Randomized Controlled Trials (RCTs) is the unbiased comparison made possible by randomization, but this is often challenged in practice when participants do not adhere to their assigned treatment. This exercise tackles the common limitation of non-compliance by guiding you through the calculation of two distinct estimands: the pragmatic intention-to-treat (ITT) effect and the explanatory complier average causal effect (CACE). Distinguishing between these estimates is crucial for interpreting the practical impact versus the physiological efficacy of an intervention .",
            "id": "4639879",
            "problem": "A public health team conducts a two-arm Randomized Controlled Trial (RCT) to evaluate a behavioral intervention intended to reduce a binary adverse outcome, where assignment is randomized but there is imperfect compliance. Let $Z \\in \\{0,1\\}$ denote random assignment to intervention ($Z=1$) versus control ($Z=0$), $A \\in \\{0,1\\}$ denote actual receipt of the intervention, and $Y \\in \\{0,1\\}$ denote the outcome indicator. Assume that randomization ensures independence between $Z$ and all potential outcomes and treatments, and that measurement is unbiased. The observed uptake probabilities are $P(A=1 \\mid Z=1)=0.80$ and $P(A=1 \\mid Z=0)=0.10$. The observed mean outcomes by assignment are $\\bar{Y}_{Z=1}=0.30$ and $\\bar{Y}_{Z=0}=0.40$, where $\\bar{Y}_{Z=z}$ denotes the mean of $Y$ among those with assignment $Z=z$.\n\nUsing only core definitions of the Intention-To-Treat (ITT) effect and the Complier Average Causal Effect (CACE), and the standard instrumental variables assumptions appropriate for an encouragement design in a randomized trial (independence of $Z$, exclusion restriction, monotonicity, and a nonzero first stage), compute the ITT effect and the CACE. Then, interpret both quantities in terms of the strengths and limitations of randomized trials with noncompliance. Express your numerical results exactly; no rounding is required. Your final numerical answer must contain the ITT effect and the CACE in that order.",
            "solution": "The problem statement is found to be valid. It is a well-posed problem in the field of epidemiology and causal inference, resting on established scientific principles and using clear, objective language. It provides all necessary data and assumptions for a unique solution without any internal contradictions or reliance on pseudoscience.\n\nThe problem asks for the computation and interpretation of two key causal estimands in a Randomized Controlled Trial (RCT) with imperfect compliance: the Intention-To-Treat (ITT) effect and the Complier Average Causal Effect (CACE).\n\nLet us define the variables as provided:\n- $Z \\in \\{0,1\\}$: Random assignment, where $Z=1$ is assignment to the intervention arm and $Z=0$ is assignment to the control arm.\n- $A \\in \\{0,1\\}$: Actual receipt of the intervention, where $A=1$ indicates receipt and $A=0$ indicates non-receipt.\n- $Y \\in \\{0,1\\}$: A binary outcome indicator, where $Y=1$ could denote the occurrence of an adverse event and $Y=0$ its non-occurrence.\n\nThe provided data are:\n- Probability of treatment uptake in the intervention arm: $P(A=1 \\mid Z=1) = 0.80$. Since $A$ is binary, this is equivalent to the expectation $E[A \\mid Z=1] = 0.80$.\n- Probability of treatment uptake in the control arm: $P(A=1 \\mid Z=0) = 0.10$. This is equivalent to the expectation $E[A \\mid Z=0] = 0.10$.\n- Mean outcome in the intervention arm: $\\bar{Y}_{Z=1} = E[Y \\mid Z=1] = 0.30$.\n- Mean outcome in the control arm: $\\bar{Y}_{Z=0} = E[Y \\mid Z=0] = 0.40$.\n\n**1. Calculation of the Intention-To-Treat (ITT) Effect**\n\nThe ITT effect is defined as the effect of treatment *assignment* on the outcome, regardless of the treatment actually received. It is calculated as the difference in the mean outcomes between the group assigned to the intervention and the group assigned to the control.\n\n$$\n\\text{ITT} = E[Y \\mid Z=1] - E[Y \\mid Z=0]\n$$\n\nUsing the provided data:\n\n$$\n\\text{ITT} = 0.30 - 0.40 = -0.10\n$$\n\nThis can be expressed as an exact fraction: $\\text{ITT} = -\\frac{1}{10}$.\n\n**2. Calculation of the Complier Average Causal Effect (CACE)**\n\nThe CACE is the average causal effect of the treatment among the subpopulation of individuals known as \"compliers.\" Under the standard instrumental variable (IV) assumptions provided in the problem statement (independence, exclusion restriction, monotonicity, and a nonzero first stage), the CACE can be estimated using the Wald estimator. This estimator is the ratio of the ITT effect on the outcome ($Y$) to the ITT effect on treatment receipt ($A$).\n\nThe formula for the CACE is:\n\n$$\n\\text{CACE} = \\frac{E[Y \\mid Z=1] - E[Y \\mid Z=0]}{E[A \\mid Z=1] - E[A \\mid Z=0]}\n$$\n\nThe numerator is the ITT effect, which we have already calculated as $-0.10$. The denominator represents the difference in the proportion of individuals receiving the treatment between the intervention and control arms. This is often referred to as the \"first stage\" effect, which quantifies the success of the encouragement ($Z$) in changing the behavior ($A$).\n\nLet's calculate the denominator:\n\n$$\nE[A \\mid Z=1] - E[A \\mid Z=0] = P(A=1 \\mid Z=1) - P(A=1 \\mid Z=0) = 0.80 - 0.10 = 0.70\n$$\n\nThe assumption of a \"nonzero first stage\" is met, as $0.70 \\neq 0$.\n\nNow, we can compute the CACE:\n\n$$\n\\text{CACE} = \\frac{-0.10}{0.70} = \\frac{-1/10}{7/10} = -\\frac{1}{7}\n$$\n\n**3. Interpretation of Results**\n\nThe problem also asks for an interpretation of these quantities in the context of the strengths and limitations of RCTs with noncompliance.\n\n- **ITT Effect Interpretation**: The ITT effect is $-0.10$. This means that *assigning* an individual to the intervention, as a policy, reduces their probability of experiencing the adverse outcome by $10$ percentage points on average, compared to assigning them to the control group. A key **strength** of the ITT estimate is that it is unbiased by confounding factors. Because it compares groups based on the initial random assignment, it preserves the baseline balance of all measured and unmeasured covariates between the two arms. This makes it a highly robust and pragmatically important estimate for evaluating the real-world effectiveness of a public health program or policy. However, its **limitation** is that it provides a diluted or conservative estimate of the treatment's true efficacy. The effect is averaged over both compliers and non-compliers (those who received the treatment and those who did not in the intervention arm), so it does not represent the effect of actually *receiving* the treatment.\n\n- **CACE Effect Interpretation**: The CACE is $-\\frac{1}{7} \\approx -0.143$. This means that for the specific subgroup of \"compliers\" (individuals who would take the intervention if assigned to it, and not take it if assigned to control), the intervention *itself* reduces the probability of the adverse outcome by approximately $14.3$ percentage points. A **strength** of the CACE is that it adjusts for noncompliance to provide an estimate of the causal effect of the treatment itself, which is often of greater biological or mechanistic interest. It is a \"de-contaminated\" estimate, representing what the effect would be in the compliant subpopulation. The **limitation** of the CACE is twofold. First, it relies on strong, untestable assumptions, particularly the exclusion restriction (assignment affects the outcome only through treatment receipt) and monotonicity (no \"defiers\" exist). If these assumptions are violated, the estimate is biased. Second, the CACE is not an effect for the entire population but only for the unobservable subgroup of compliers. Its generalizability to other groups (e.g., \"always-takers\" or \"never-takers\") or to the full population is not guaranteed, which can limit its policy relevance compared to the ITT. The CACE is larger in magnitude ($-0.143$ vs. $-0.10$) than the ITT effect, which is expected, as the ITT effect is diluted by the $30\\%$ non-compliance ($20\\%$ in the treatment arm and $10\\%$ in the control arm who \"cross over\"). The CACE essentially re-scales the ITT effect by the proportion of compliers in the population, which is estimated by the denominator $E[A|Z=1]-E[A|Z=0]=0.70$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} -\\frac{1}{10} & -\\frac{1}{7} \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "Not all trials aim to prove a new treatment is better; many are designed to demonstrate that it is not unacceptably worse than an existing standard, a concept known as non-inferiority. This problem introduces the statistical framework for these trials, where a conclusion is reached by comparing the confidence interval of the effect estimate to a pre-specified non-inferiority margin, $\\Delta$. This practice will solidify your understanding of how to set up, analyze, and interpret non-inferiority trials, a common and important design in modern clinical research .",
            "id": "4639899",
            "problem": "A parallel-group randomized controlled trial (RCT) compares an experimental therapy with a standard therapy on a binary adverse outcome measured at $30$ days. The non-inferiority margin on the absolute risk difference is pre-specified as $\\Delta = 0.05$, justified during planning by historical data indicating a control-group event risk of $0.20$ under usual care. In the executed RCT, $n_{E} = 1000$ participants are randomized to the experimental therapy and $n_{C} = 1000$ participants are randomized to the control therapy. The observed numbers of events are $220$ in the experimental group and $240$ in the control group, yielding observed risks $\\hat{p}_{E} = 0.22$ and $\\hat{p}_{C} = 0.24$.\n\nUsing the binomial sampling model and the Central Limit Theorem as the starting point, derive the two-sided $95\\%$ confidence interval for the absolute risk difference $\\text{RD} = p_{E} - p_{C}$, where $p_{E}$ and $p_{C}$ are the true risks in the experimental and control groups, respectively. Then, apply the standard non-inferiority decision rule for the risk difference framework to determine whether the experimental therapy is non-inferior to the control therapy with margin $\\Delta = 0.05$. Round the upper limit of the confidence interval to four significant figures and report this upper limit as your final numeric answer in decimal form (no units). In your work, justify the decision rule from first principles of confidence intervals and discuss how randomization supports the validity of this inference, as well as limitations specific to non-inferiority trials that could affect interpretation when the observed control risk ($0.24$) differs from the historical risk ($0.20$).",
            "solution": "The problem will first be subject to rigorous validation.\n\n**Problem Validation**\n\n**Step 1: Extracted Givens**\n-   Study design: Parallel-group randomized controlled trial.\n-   Comparison groups: Experimental therapy versus standard therapy.\n-   Outcome: Binary adverse outcome measured at $30$ days.\n-   Non-inferiority margin: $\\Delta = 0.05$ (on the absolute risk difference scale).\n-   Historical control-group event risk for justification of $\\Delta$: $0.20$.\n-   Experimental group sample size: $n_{E} = 1000$.\n-   Control group sample size: $n_{C} = 1000$.\n-   Number of events in experimental group: $220$.\n-   Number of events in control group: $240$.\n-   Observed risk in experimental group: $\\hat{p}_{E} = 0.22$.\n-   Observed risk in control group: $\\hat{p}_{C} = 0.24$.\n-   Confidence level for interval estimation: $95\\%$.\n-   Statistical framework: Binomial sampling model and Central Limit Theorem.\n-   Tasks:\n    1.  Derive and calculate the $95\\%$ confidence interval for the risk difference $\\text{RD} = p_{E} - p_{C}$.\n    2.  Apply the non-inferiority decision rule.\n    3.  Justify the decision rule.\n    4.  Discuss the role of randomization.\n    5.  Discuss limitations related to the discrepancy between observed and historical control risk.\n    6.  Report the upper limit of the confidence interval rounded to four significant figures.\n\n**Step 2: Validation Using Extracted Givens**\nThe problem is assessed to be **valid**. It is scientifically grounded, employing standard concepts and methodologies from biostatistics and epidemiology, specifically the design and analysis of non-inferiority clinical trials. The problem is well-posed, providing all necessary data ($n_E, n_C$, event counts) and parameters ($\\Delta$, confidence level) for a unique and stable solution. The data are internally consistent (e.g., $220/1000 = 0.22$). The language is objective and unambiguous. The problem represents a standard, non-trivial application of statistical principles to a realistic scenario in medical research.\n\n**Derivation and Solution**\n\nLet $p_{E}$ and $p_{C}$ be the true, unknown probabilities (risks) of the adverse outcome in the populations receiving the experimental and control therapies, respectively. The parameter of interest is the absolute risk difference, $\\text{RD} = p_{E} - p_{C}$.\n\nLet $X_{E}$ and $X_{C}$ be the number of events in the experimental and control groups. Under the binomial sampling model, $X_{E} \\sim \\text{Binomial}(n_{E}, p_{E})$ and $X_{C} \\sim \\text{Binomial}(n_{C}, p_{C})$. The unbiased estimators for the risks are the sample proportions, $\\hat{p}_{E} = X_{E}/n_{E}$ and $\\hat{p}_{C} = X_{C}/n_{C}$. The point estimator for the risk difference is $\\widehat{\\text{RD}} = \\hat{p}_{E} - \\hat{p}_{C}$.\n\nThe variance of the sample proportions are $\\text{Var}(\\hat{p}_{E}) = \\frac{p_{E}(1-p_{E})}{n_{E}}$ and $\\text{Var}(\\hat{p}_{C}) = \\frac{p_{C}(1-p_{C})}{n_{C}}$. Because the groups are independent due to randomization, the variance of the difference estimator is the sum of the variances:\n$$ \\text{Var}(\\widehat{\\text{RD}}) = \\text{Var}(\\hat{p}_{E}) + \\text{Var}(\\hat{p}_{C}) = \\frac{p_{E}(1-p_{E})}{n_{E}} + \\frac{p_{C}(1-p_{C})}{n_{C}} $$\nThis variance is unknown and must be estimated from the data. The estimated standard error of $\\widehat{\\text{RD}}$ is:\n$$ \\widehat{\\text{SE}}(\\widehat{\\text{RD}}) = \\sqrt{\\frac{\\hat{p}_{E}(1-\\hat{p}_{E})}{n_{E}} + \\frac{\\hat{p}_{C}(1-\\hat{p}_{C})}{n_{C}}} $$\nThe sample sizes ($n_{E} = 1000$, $n_{C} = 1000$) are large, so by the Central Limit Theorem, the sampling distribution of $\\widehat{\\text{RD}}$ is approximately Normal: $\\widehat{\\text{RD}} \\sim \\mathcal{N}(\\text{RD}, \\text{SE}(\\widehat{\\text{RD}})^2)$.\n\nA two-sided $(1-\\alpha)100\\%$ confidence interval (CI) for the true risk difference $\\text{RD}$ is given by:\n$$ \\widehat{\\text{RD}} \\pm z_{1-\\alpha/2} \\times \\widehat{\\text{SE}}(\\widehat{\\text{RD}}) $$\nFor a $95\\%$ confidence interval, $\\alpha = 0.05$, and the critical value from the standard normal distribution is $z_{1-0.05/2} = z_{0.975} \\approx 1.96$.\n\nWe now substitute the given values:\n-   $\\hat{p}_{E} = \\frac{220}{1000} = 0.22$\n-   $\\hat{p}_{C} = \\frac{240}{1000} = 0.24$\n-   The point estimate for the risk difference is $\\widehat{\\text{RD}} = 0.22 - 0.24 = -0.02$.\n-   The estimated standard error is:\n$$ \\widehat{\\text{SE}}(\\widehat{\\text{RD}}) = \\sqrt{\\frac{0.22(1-0.22)}{1000} + \\frac{0.24(1-0.24)}{1000}} = \\sqrt{\\frac{0.22(0.78) + 0.24(0.76)}{1000}} $$\n$$ \\widehat{\\text{SE}}(\\widehat{\\text{RD}}) = \\sqrt{\\frac{0.1716 + 0.1824}{1000}} = \\sqrt{\\frac{0.354}{1000}} = \\sqrt{0.000354} \\approx 0.01881489 $$\nThe margin of error for the $95\\%$ CI is $1.96 \\times 0.01881489 \\approx 0.03687718$.\nThe $95\\%$ confidence interval is:\n$$ -0.02 \\pm 0.03687718 $$\nThis yields the interval $[-0.05687718, 0.01687718]$.\n\n**Non-Inferiority Assessment**\nThe goal is to test if the experimental therapy is non-inferior to the control. Since the outcome is adverse, non-inferiority means the risk $p_{E}$ is not unacceptably larger than $p_{C}$. The hypotheses are:\n-   Null Hypothesis ($H_{0}$): The experimental therapy is inferior, $p_{E} - p_{C} \\ge \\Delta$.\n-   Alternative Hypothesis ($H_{1}$): The experimental therapy is non-inferior, $p_{E} - p_{C} < \\Delta$.\nHere, the pre-specified non-inferiority margin is $\\Delta = 0.05$.\n\nThe decision rule is: If the upper bound of the two-sided $95\\%$ confidence interval for the risk difference $p_{E} - p_{C}$ is less than the margin $\\Delta$, we reject $H_{0}$ and conclude that the experimental therapy is non-inferior. This procedure is equivalent to a one-sided hypothesis test at the $\\alpha = 0.025$ significance level.\n\nThe upper limit of our calculated $95\\%$ CI is $0.01687718$.\nWe compare this to the margin $\\Delta = 0.05$.\nSince $0.01687718 < 0.05$, the upper bound of the confidence interval lies below the non-inferiority margin.\nTherefore, we conclude that the experimental therapy is non-inferior to the standard therapy with respect to the risk of the adverse outcome.\n\n**Justification of the Decision Rule**\nA $95\\%$ confidence interval represents a range of plausible values for the true parameter, consistent with the observed data. The construction guarantees that, under repeated sampling, $95\\%$ of such intervals will contain the true parameter value. When we state that the $95\\%$ CI for $\\text{RD}$ is $[-0.057, 0.017]$, we are asserting with $95\\%$ confidence that the true risk difference lies within this range. The decision rule links this estimation concept to hypothesis testing. If the entire interval of plausible values for $\\text{RD}$ is less than $\\Delta$, it provides strong evidence that the true $\\text{RD}$ is less than $\\Delta$. This refutes the premise of the null hypothesis ($H_0: \\text{RD} \\ge \\Delta$), leading to its rejection.\n\n**Role of Randomization**\nRandomization is the fundamental design feature that supports this statistical inference. By randomly assigning participants to the experimental or control group, we ensure that, on average, the two groups are comparable with respect to all baseline characteristics, both measured and unmeasured. This process minimizes selection bias and confounding. The resulting balance of prognostic factors implies that any systematic difference in outcomes observed between the groups can be confidently attributed to the effects of the therapies themselves. This provides the basis for a causal interpretation of the estimated risk difference and validates the use of statistical tests and confidence intervals, which assume independent groups and unbiased effect estimation.\n\n**Limitation: Discrepancy in Control Group Risk**\nA critical limitation in interpreting this non-inferiority finding arises from the discrepancy between the historical control-group risk ($0.20$) used to justify the margin $\\Delta = 0.05$ and the observed control-group risk in the trial ($\\hat{p}_{C} = 0.24$). The choice of $\\Delta$ is not arbitrary; it is intended to ensure that the experimental therapy preserves a clinically acceptable fraction of the standard therapy's established effect. This relies on the \"constancy assumption\" â€” that the effect of the standard therapy is similar in the current trial to what it was in past trials. The higher-than-expected control event rate suggests that the patient population in this trial may be at higher risk or otherwise different from the historical population. This challenges the validity of the pre-specified margin $\\Delta = 0.05$. The clinical meaning of preserving the standard therapy's effect up to a loss of $5\\%$ absolute risk may differ in a population with a $24\\%$ baseline risk versus a $20\\%$ baseline risk. The finding of non-inferiority must be interpreted with caution, as the scientific basis for the chosen margin may be compromised.\n\nThe upper limit of the confidence interval is $0.01687718$. Rounded to four significant figures, this is $0.01688$.",
            "answer": "$$\n\\boxed{0.01688}\n$$"
        }
    ]
}